{
    "2019-03-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why You Should Buy ABBV Stock for Income and Value",
                "features": {
                    "keywords": [
                        "buy",
                        "ABBV",
                        "income",
                        "value"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "FDA puts partial hold on clinical trials of AbbVie's cancer drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "hold",
                        "clinical trials",
                        "cancer drug"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-11",
                "original_text": "AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock down",
                        "FDA",
                        "hold",
                        "venetoclax",
                        "multiple myeloma"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-12",
                "original_text": "AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "update",
                        "VENCLEXTA",
                        "VENCLYXTO",
                        "venetoclax",
                        "multiple myeloma"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-13",
                "original_text": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock sinks",
                        "market gains"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}